Emergent BioSolutions (EBS) Misses Q2 View By 17c; Issues FY08 Revenue Guidance
Tweet Send to a Friend
Emergent BioSolutions (NYSE: EBS) reports Q2 EPS of $0.06, 17 cents below the analyst estimate of $0.23. Revenues ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
